KALY - Kali-Extracts Advances New Cannabis Biopharmaceutical Capital Investment
November 21 2019 - 3:39PM
InvestorsHub NewsWire
KALY - Kali-Extracts Advances New
Cannabis Biopharmaceutical Capital Investment
Dallas, TX --
November 21, 2019 -- InvestorsHub NewsWire -- Kali-Extracts,
Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today confirmed introducing a third option to
compete with the two acquisition offers currently being entertained
by KALY management. KALY has recently announced receiving two
inquiries into the acquisition of the company’s cannabis
biopharmaceutical technology valuing the technology at $50
million. KALY management is entertaining the inquiries but
indicates that the $50 million valuation is too low. KALY has
a U.S. Patented Cannabis Extraction Process and is developing
treatments for various medical conditions (see below).
Doctors working with KALY on the treatment developments have
compared KALY’s technology to GW Pharmaceuticals’ and indicated the
KALY solutions could be superior to GW Pharma’s. KALY
management yesterday announced that in addition to entertaining the
two acquisition opportunities that could infuse financing that
accelerates its cannabis extract biopharmaceutical technology
developments, that the company is introducing a third option that
would not involve a sale of KALY’s biopharmaceutical technology
asset, but would otherwise restructure the asset within KALY’s
current corporate structure to facilitate a major infusion of
investment capital. KALY management plans to finalize the third
option plans within the next two weeks and make them
public.
KALY’s cannabis
biopharmaceutical technology intellectual property portfolio
contains a deep pipeline of cannabinoid product candidates
including four distinct compounds listed
here:
Chronic Obstructive Pulmonary
Disease (COPD) - The
market for COPD treatment is anticipated to reach $14 billion by
2025;
Type 2
Diabetes - The market for
Type 2 Diabetes is expected to be a $64 billion market by
2026;
Cancer Pain
Management - The overall
pain management treatment market is anticipated to reach $83
billion by 2024, and
Epilepsy
- The market for epilepsy treatment is
anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted
and the next phase of research now moving forward, KALY recently
filed for a new patent application specifically on its formulation
for symptoms associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark
on the name RespRx as the brand name for its CBD
formulation to treat the symptoms associated with COPD and other
similar respiratory conditions. The market
for COPD treatment is anticipated to reach $14 billion by
2025.
In addition to KALY’s ongoing efforts to develop
prescription therapies, KALY has initiated a program to certify its
proprietary CBD extracts derived from KALY’s U.S. Patented
Extraction Process as an Over-The-Counter (OTC) drug under the
requirements prescribed by the U.S. Food and Drug
Administration.
To stay abreast
of the latest developments and learn more about the company visit
https://www.kali-extracts.com/.
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024